跳至主要内容
临床试验/JPRN-UMIN000024928
JPRN-UMIN000024928尚未招募未知

Real world molecular testing among patients with EGFR mutation positive NSCLC following progression on an EGFR-TKI in Japa

AstraZeneca K.K.0 个研究点目标入组 300 人开始时间: 2016年11月24日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 1.Age more than 20 y.o.
  • 2.Able to obtain Informed Consent Form
  • 3.Diagnosed advanced non-small cell lung cancer with EGFR mutation
  • 4.Investigator judged "Disease Progress" during EGFR-TKI treatment.

排除标准

  • 1.Patients who the investigator judged retrospective review of medical charts or information on pre-progression medical history at the participating site cannot be done.
  • 2.Patients already given T790M targeting EGFR-TKI
  • 3.Patients having EGFR-TKI treatment with more than two different TKIs, except EGFR-TKI switching patients with toxicity reason

研究者

相似试验